TrialHeadache2020

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.

Gregor Broessner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.